

RECORDATI: PERFORMANCE SHARE PLAN 2023-2025 ASSIGNMENT OF RIGHTS PROVIDED UNDER THE FIRST CYCLE

Milan, 27th June 2023 – With reference to the incentive plan of Recordati S.p.A. (“Recordati” or the “Company”) known as “Performance Share Plan 2023-2025” (the “Plan”) approved by the Company’s Shareholders’ Meeting on 21st April 2023, notice is hereby given that today the Board of Directors of the Company, upon proposal of the Company’s Remuneration and Nominations Committee to the extent of its competence and in accordance with the provisions of the relevant regulations, resolved to grant (free of charge) to Beneficiaries of the Plan a total of no. 440,485 rights (the “Rights”) to receive, also free of charge, a certain number of ordinary shares of the Company - to be defined on the basis of the implementation of the Plan with respect to the Vested Rights – falling within the first allocation cycle of the Plan, of which no. 26,111 Rights to the Chief Executive Officer of Recordati.

Table No. 1 referred to in paragraph 4.24 of Annex 3A, Schedule 7, of the Issuers' Regulations No. 11971/1999 regarding the implementation of the assignments provided by the first cycle of the Plan will be published in accordance with the procedures and timing set forth in Article 84-bis, paragraph 5, letter a), of the Issuers' Regulations No. 11971/1999 itself.

For more information on the Plan, please refer to the related Information Document, which can be retrieved on the Company's website in the “Investors” section under “Shareholders’ Meetings”.

Recordati (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan, Australia and New Zealand, China and South Korea. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a global specialised business, dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2022 was € 1,853.3 million, operating income was € 437.3 million and net income was € 312.3 million.

For further information:

Recordati website: www.recordati.it

Investor Relations

Federica De Medici
(39) 02 48787146
e-mail: investorelations@recordati.it

Investor Relations

Lucia Abbatantuoni
(39) 02 48787213
e-mail: investorelations@recordati.it

Media Relations

Brunswick: Barbara Scalchi / Andrea Mormandi
(39) 02 9288 6200
e-mail: recordati@brunswickgroup.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1
20148 Milano, Italy
Ph. (39) 02 487871
Fax (39) 02 40073747
www.recordati.com

Share Capital € 26.140.644,50 fully paid-up
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150
Tax Code/VAT No. 00748210150
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l